
James D. Douketis, Alex C. Spyropoulos, Frederick A. Spencer, Michael Mayr, Amir K. Jaffer, Mark H. Eckman, Andrew S. Dunn and Regina Kunz

Chest 2012;141:e326S-e350S
DOI 10.1378/chest.11-2298

The online version of this article, along with updated information and services can be found online on the World Wide Web at:
http://chestjournal.chestpubs.org/content/141/2_suppl/e326S.full.html

Supplemental material related to this article is available at:
http://chestjournal.chestpubs.org/content/suppl/2012/02/03/141.2_suppl.e326S.DC1.html

Chest is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright 2012 by the American College of Chest Physicians, 3300 Dundee Road, Northbrook, IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder. (http://chestjournal.chestpubs.org/site/misc/reprints.xhtml)
ISSN: 0012-3692

Downloaded from chestjournal.chestpubs.org at Washington University on March 5, 2012 © 2012 American College of Chest Physicians
Perioperative Management of Antithrombotic Therapy

Background: This guideline addresses the management of patients who are receiving anticoagulant or antiplatelet therapy and require an elective surgery or procedure.


Results: In patients requiring vitamin K antagonist (VKA) interruption before surgery, we recommend stopping VKAs 5 days before surgery instead of a shorter time before surgery (Grade 1B). In patients with a mechanical heart valve, atrial fibrillation, or VTE at high risk for thromboembolism, we suggest bridging anticoagulation instead of no bridging during VKA interruption (Grade 2C); in patients at low risk, we suggest no bridging instead of bridging (Grade 2C). In patients who require a dental procedure, we suggest continuing VKAs with an oral prohemostatic agent or stopping VKAs 2 to 3 days before the procedure instead of alternative strategies (Grade 2C).

In moderate- to high-risk patients who are receiving acetylsalicylic acid (ASA) and require non-cardiac surgery, we suggest continuing ASA around the time of surgery instead of stopping ASA 7 to 10 days before surgery (Grade 2C). In patients with a coronary stent who require surgery, we recommend deferring surgery > 6 weeks after bare-metal stent placement and > 6 months after drug-eluting stent placement instead of undertaking surgery within these time periods (Grade 1C); in patients requiring surgery within 6 weeks of bare-metal stent placement or within 6 months of drug-eluting stent placement, we suggest continuing antiplatelet therapy perioperatively instead of stopping therapy 7 to 10 days before surgery (Grade 2C).

Conclusions: Perioperative antithrombotic management is based on risk assessment for thromboembolism and bleeding, and recommended approaches aim to simplify patient management and minimize adverse clinical outcomes.

Abbreviations: aPTT = activated partial thromboplastin time; ASA = acetylsalicylic acid; AT8 = Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition); AT9 = Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines; ATE = arterial thromboembolism; CABG = coronary artery bypass graft; CHADS2 = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack; INR = international normalized ratio; LMWH = low-molecular-weight heparin; PICO = population, intervention, comparator, and outcome; SC = subcutaneous; UFH = unfractionated heparin; VKA = vitamin K antagonist

Summary of Recommendations

Note on Shaded Text: Throughout this guideline, shading is used within the summary of recommendations sections to indicate recommendations that are newly added or have been changed since the publication of Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Recommendations that remain unchanged are not shaded.
2.1. In patients who require temporary interruption of a VKA before surgery, we recommend stopping VKAs approximately 5 days before surgery instead of stopping VKAs a shorter time before surgery (Grade 1C).

2.2. In patients who require temporary interruption of a VKA before surgery, we recommend resuming VKAs approximately 12 to 24 h after surgery (evening of or next morning) and when there is adequate hemostasis instead of later resumption of VKAs (Grade 2C).

2.4. In patients with a mechanical heart valve, atrial fibrillation, or VTE at high risk for thromboembolism, we suggest bridging anticoagulation instead of no bridging during interruption of VKA therapy (Grade 2C).

Remarks: Patients who place a higher value on avoiding perioperative bleeding than on avoiding perioperative thromboembolism are likely to decline heparin bridging.

In patients with a mechanical heart valve, atrial fibrillation, or VTE at low risk for thromboembolism, we suggest no bridging instead of bridging anticoagulation during interruption of VKA therapy (Grade 2C).

In patients with a mechanical heart valve, atrial fibrillation, or VTE at moderate risk for thromboembolism, the bridging or no-bridging approach chosen is, as in the higher- and lower-risk patients, based on an assessment of individual patient- and surgery-related factors.

2.5. In patients who require a minor dental procedure, we suggest continuing VKAs with coadministration of an oral prohemostatic agent or stopping VKAs 2 to 3 days before the procedure instead of alternative strategies (Grade 2C). In patients who require minor dermatologic procedures and are receiving VKA therapy, we suggest continuing VKAs around the time of the procedure and optimizing local hemostasis instead of other strategies (Grade 2C). In patients who require cataract surgery and are receiving VKA therapy, we suggest continuing VKAs around the time of the surgery instead of other strategies (Grade 2C).

3.4. In patients who are receiving ASA for the secondary prevention of cardiovascular disease and are having minor dental or dermatologic procedures or cataract surgery, we suggest continuing ASA around the time of the procedure instead of stopping ASA 7 to 10 days before the procedure (Grade 2C).

3.5. In patients at moderate to high risk for cardiovascular events who are receiving ASA therapy and require noncardiac surgery, we suggest continuing ASA around the time of surgery instead of stopping ASA 7 to 10 days before surgery (Grade 2C). In patients at low risk for cardiovascular events who are receiving ASA therapy, we suggest stopping ASA 7 to 10 days before surgery instead of continuation of ASA (Grade 2C).

3.6. In patients who are receiving ASA and require CABG surgery, we suggest continuing ASA around the time of surgery instead of stopping ASA 7 to 10 days before surgery (Grade 2C). In patients who are receiving dual antiplatelet drug therapy and require CAGB surgery, we suggest continuing ASA around the time of surgery and stopping clopidogrel/prasugrel 5 days before surgery instead of continuing dual antiplatelet therapy around the time of surgery (Grade 2C).

3.7. In patients with a coronary stent who are receiving dual antiplatelet therapy and require surgery, we recommend deferring surgery for at least 6 weeks after placement of a bare-metal stent and for at least 6 months after placement of a drug-eluting stent. If surgery cannot be deferred, we suggest continuing dual antiplatelet therapy and stopping clopidogrel/prasugrel 5 days before surgery instead of continuing dual antiplatelet therapy around the time of surgery (Grade 2C).
of a drug-eluting stent instead of undertaking surgery within these time periods (Grade 1C). In patients who require surgery within 6 weeks of placement of a bare-metal stent or within 6 months of placement of a drug-eluting stent, we suggest continuing dual antiplatelet therapy around the time of surgery instead of stopping dual antiplatelet therapy 7 to 10 days before surgery (Grade 2C).

4.2. In patients who are receiving bridging anticoagulation with therapeutic-dose IV UFH, we suggest stopping UFH 4 to 6 h before surgery instead of closer to surgery (Grade 2C).

Remarks: Patients who are more concerned about avoiding the unknown, but potentially large increase in bleeding risk associated with the perioperative continuation of dual antiplatelet therapy than avoiding the risk for coronary stent thrombosis are unlikely to choose continuation of dual antiplatelet therapy.

4.3. In patients who are receiving bridging anticoagulation with therapeutic-dose SC LMWH, we suggest administering the last preoperative dose of LMWH approximately 24 h before surgery instead of 12 h before surgery (Grade 2C).

4.4. In patients who are receiving bridging anticoagulation with therapeutic-dose SC LMWH and are undergoing high-bleeding-risk surgery, we suggest resuming therapeutic-dose LMWH 48 to 72 h after surgery instead of resuming LMWH within 24 h after surgery (Grade 2C).

The perioperative management of patients who are receiving vitamin K antagonists (VKAs) or antiplatelet drugs and require a surgical or invasive procedure presents a dilemma for practicing clinicians. This clinical problem affects an estimated 250,000 patients annually in North America alone and is of interest to a wide spectrum of clinicians, including internists, surgeons, anesthesiologists, family physicians, and dentists.1,2 However, there is a relative paucity of well-designed clinical trials to inform best practices and a disproportionately large number of methodologically weak observational studies.4,8 The aims of this article are to (1) provide guidelines for perioperative antithrombotic management that reflect the quality of the available evidence and (2) provide guidance for clinicians as to the practical aspects of antithrombotic management in the perioperative setting.

The current iteration of this article differs from that of Douketis et al6 in the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) (AT8), in the following ways:

- There is a downgrading of several recommendations. This reflects the emergence of additional evidence and, in general, a higher threshold for conferring strong (level 1) recommendations, which has been adopted across the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (AT9).
- There are fewer recommendations in AT9. We aimed to make evidence-based recommendations on areas where studies exist that are directly pertinent to the clinical questions we developed, which were based on the population, intervention, comparator, and outcome (PICO) format. Whenever possible, we relied less on indirect evidence from studies in the nonperioperative setting.
- For areas in which a PICO question was not developed but are, nonetheless, considered relevant for everyday practice, we have provided narrative comments in the text without specific recommendations.
- The antithrombotic management of patients requiring urgent surgery is now addressed in the article by Falck-Ytter et al8 in this guideline.

The following definitions and qualifying remarks are aimed to facilitate an understanding of this article and its accompanying recommendations:

- Bridging anticoagulation. In the absence of a universally accepted definition,6,10,11 we define bridging anticoagulation as the administration of a short-acting anticoagulant, consisting of subcutaneous (SC) low-molecular-weight heparin (LMWH) or IV unfractionated heparin (UFH), for an ~10- to 12-day period during interruption of VKA therapy when the international normalized ratio (INR) is not within a therapeutic range.
- Therapeutic intent of heparin bridging and dose regimens. Bridging anticoagulation aims to minimize the risk for arterial thromboembolism (ATE), such as stroke and systemic embolism, in patients with a mechanical heart valve or atrial fibrillation and to minimize the risk for recurrent thrombosis in patients with prior VTE. The argument for using a high-dose (or therapeutic-dose) heparin regimen to prevent ATE is based on two considerations. First, this dose regimen with LMWH or UFH is comparable to a therapeutic-dose VKA regimen when used for the prevention of ATE in patients with a mechanical heart valve and the treatment of acute
VTE.\textsuperscript{12,13} Second, a therapeutic-dose regimen of idraparinux, a factor Xa antagonist with LMWH-like anticoagulant properties, is as efficacious as a VKA to prevent ATE in patients with atrial fibrillation.\textsuperscript{14} However, its efficacy to prevent perioperative ATE is not established. A low-dose (or prophylactic-dose) heparin regimen is known to prevent postoperative VTE, but its efficacy to prevent ATE is also not established, and the biological plausibility to support its efficacy for this therapeutic aim may be questioned.\textsuperscript{15} Finally, the use of LMWH or UFH as perioperative bridging is considered an off-label use of these drugs because their use is not approved by regulatory authorities or drug manufacturers in this clinical setting as a bridging agent.

- **Bridging dose regimens.** Three dose regimens have been studied:

1. A high-dose (therapeutic-dose) heparin bridging regimen involves administering an anticoagulant dose that is similar to that used for the treatment of acute VTE or an acute coronary syndrome (eg, enoxaparin 1 mg/kg bid or 1.5 mg/kg daily, dalteparin 100 International Units/kg bid or 200 International Units/kg daily; tinzaparin 175 International Units/kg daily, IV UFH to attain an activated partial thromboplastin time [aPTT] 1.5 to 2 times the control aPTT).

2. A low-dose (prophylactic-dose) heparin regimen involves administering a dose that is used, typically, to prevent postoperative VTE (eg, enoxaparin 30 mg bid or 40 mg daily, dalteparin 5,000 International Units daily; UFH 5,000-7,500 International Units bid).

3. An intermediate-dose regimen has recently been studied for bridging and is intermediate in anticoagulant intensity between high- and low-dose regimens (eg, enoxaparin 40 mg bid).

- Our recommendations relating to the need for bridging anticoagulation (section 2.4) will not refer to a specific bridging dose regimen and will deal with the issue of whether bridging is needed in a more generic sense.

- Our recommendations relating to the perioperative management of patients who are receiving antithrombotic therapy (section 4.0) will refer to a therapeutic-dose bridging regimen because it is the most widely studied and most widely used in clinical practice. It is also the dose regimen that we consider most important for practice guidelines because it has the potential to confer the greatest therapeutic benefit and the greatest harm. (We acknowledge that different bridging regimens may be used and that such regimens may have potential advantages or drawbacks compared with a therapeutic-dose regimen.)

- **VKAs.** Although several VKAs are available for clinical use, including warfarin, acenocoumarol, phenprocoumon, and anisindione,\textsuperscript{16} our recommendations will refer to warfarin because pertinent studies are dominated by warfarin use, with little or no study of other VKAs.

### Practical Aspects of Perioperative Antithrombotic Therapy Management

The perioperative management of patients who are receiving antithrombotic therapy is based on (1) an assessment of patient risk for thromboembolism and (2) an assessment of risk for perioperative bleeding. Addressing these issues will determine whether antithrombotic therapy is interrupted around the time of the surgery or procedure and, if so, whether bridging anticoagulation is considered. This article focuses on the three dominant clinical indications for VKA therapy: mechanical heart valves, chronic atrial fibrillation, and VTE.

To date, there are no validated risk stratification schemes to reliably separate VKA-treated patients into risk strata for thromboembolism and bleeding. Of necessity, our recommendations are based largely on indirect evidence and clinical experience.\textsuperscript{17-20} These risk stratification schemes are meant to provide general guidance; however, patient management may vary depending on individual patient characteristics, the surgery or procedure type, and patient values and preferences.

### Assessing Risk for Thromboembolism

Assessing patient risk for thromboembolism during the perioperative interruption of antithrombotic therapy is distinguished from assessing patient risk for postoperative VTE. In the former setting, patients are already receiving antithrombotic therapy, and the aim is mainly to prevent ATE, in some instances, with heparin bridging, whereas in the latter setting, the focus is on preventing postoperative VTE with de novo use of antithrombotic drugs.

The suggested thromboembolic risk stratification shown in Table 1 is based largely on indirect evidence from studies outside of the perioperative setting involving patients with a mechanical heart valve,\textsuperscript{21-23} chronic atrial fibrillation,\textsuperscript{2,3,24-27} or VTE\textsuperscript{28-30} who either were not receiving anticoagulation (ie, placebo instead of a VKA in patients with chronic atrial fibrillation) or were receiving less-effective treatment (eg, ASA instead...
Table 1—[Introduction] Suggested Risk Stratification for Perioperative Thromboembolism

<table>
<thead>
<tr>
<th>Indication for VKA Therapy</th>
<th>Risk Stratification</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mechanical Heart Valve</td>
</tr>
<tr>
<td></td>
<td>Attral Fibrillation</td>
</tr>
<tr>
<td></td>
<td>VTE</td>
</tr>
<tr>
<td>High</td>
<td>• Any mitral valve prosthesis</td>
</tr>
<tr>
<td></td>
<td>• Any caged-ball or tilting disc aortic valve prosthesis</td>
</tr>
<tr>
<td></td>
<td>• Recent (within 6 mo) stroke or transient ischemic attack</td>
</tr>
<tr>
<td></td>
<td>• CHADS 2 score of 5 or 6</td>
</tr>
<tr>
<td></td>
<td>• Recent (within 3 mo) stroke or transient ischemic attack</td>
</tr>
<tr>
<td></td>
<td>• Severe thrombophilia (eg, deficiency of protein C, protein S, or antithrombin; antiphospholipid antibodies; multiple abnormalities)</td>
</tr>
<tr>
<td>Moderate</td>
<td>• Bileaflet aortic valve prosthesis and one or more of the following risk factors: atrial fibrillation, prior stroke or transient ischemic attack, hypertension, diabetes, congestive heart failure, age &gt; 75 y</td>
</tr>
<tr>
<td></td>
<td>• CHADS 2 score of 3 or 4</td>
</tr>
<tr>
<td></td>
<td>• VTE within the past 3-12 mo</td>
</tr>
<tr>
<td></td>
<td>• Nonsevere thrombophilia (eg, heterozygous factor V Leiden or prothrombin gene mutation)</td>
</tr>
<tr>
<td></td>
<td>• Recurrent VTE</td>
</tr>
<tr>
<td></td>
<td>• Active cancer (treated within 6 mo or palliative)</td>
</tr>
<tr>
<td>Low</td>
<td>• Bileaflet aortic valve prosthesis without atrial fibrillation and no other risk factors for stroke</td>
</tr>
<tr>
<td></td>
<td>• CHADS 2 score of 0 to 2 (assuming no prior stroke or transient ischemic attack)</td>
</tr>
<tr>
<td></td>
<td>• VTE &gt; 12 mo previous and no other risk factors</td>
</tr>
</tbody>
</table>

CHADS 2 = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, and stroke or transient ischemic attack; VKA = vitamin K antagonist.

*High-risk patients may also include those with a prior stroke or transient ischemic attack occurring > 3 mo before the planned surgery and a CHADS 2 score < 5, those with prior thromboembolism during temporary interruption of VKAs, or those undergoing certain types of surgery associated with an increased risk for stroke or other thromboembolism (eg, cardiac valve replacement, carotid endarterectomy, major vascular surgery).
Second, a distinction should be made as to bleeding risk when anticoagulants are used as heparin bridging and when these agents are used to prevent postoperative venous thrombosis. In the former clinical setting, high-dose (or therapeutic-dose) bridging anticoagulation is administered, whereas in the latter setting, low-dose anticoagulants are used. The importance of surgical bleeding risk, therefore, is heightened in the setting of heparin bridging because of the potential to induce bleeding complications.

Providing an evidence-based scheme that stratifies surgeries and procedures according to the risk for bleeding in the context of perioperative antithrombotic drug use and, in particular, perioperative heparin bridging administration is problematic because the available evidence on such bleeding risk is based mainly on case series involving selected types of surgery. Furthermore, although there are schemes that stratify patients according to the expected intraoperative blood loss, these classifications have not been prospectively validated and do not account for the effects of perioperative use of antithrombotic drugs. Consequently, rather than propose a multiteried scheme that encompasses most surgery or procedure types that would be entirely subjective, we have identified a group of surgeries and procedures that appear to be associated with a high risk for bleeding in the context of perioperative anticoagulant and antiplatelet drug use.

Surgeries and procedures associated with an increased bleeding risk during perioperative antithrombotic drug administration include the following:

- Urologic surgery and procedures consisting of transurethral prostate resection, bladder resection, or tumor ablation; nephrectomy; or kidney biopsy in part due to untreated tissue damage (after prostatectomy) and endogenous urokinase release\(^ {32-34} \)
- Pacemaker or implantable cardioverter-defibrillator device implantation in which separation of infraclavicular fascial layers and lack of suturing of unopposed tissues within the device pocket may predispose to hematoma development\(^ {35-38} \)
- Colonic polyp resection, typically of large (ie, > 1-2 cm long) sessile polyps, in which bleeding may occur at the transected stalk following hemostatic plug release\(^ {39} \)
- Surgery and procedures in highly vascular organs, such as the kidney, liver, and spleen
- Bowel resection in which bleeding may occur at the bowel anastomosis site
- Major surgery with extensive tissue injury (eg, cancer surgery, joint arthroplasty, reconstructive plastic surgery)\(^ {40,41} \)
- Cardiac, intracranial, or spinal surgery, especially as small pericardial, intracerebral, or epidural bleeds can have serious clinical consequences\(^ {42-44} \)

**Standardized Perioperative Anticoagulant Therapy Protocols**

Patients who are receiving warfarin and other antithrombotic drugs and require elective surgery or procedures may benefit from management according to standardized, institution-specific protocols. Although there are no randomized trials showing that a standard management approach improves clinical outcomes and minimizes health-care resource use, observational studies that incorporated standardized perioperative anticoagulant therapy protocols and heparin bridging regimens had low rates of thromboembolic and bleeding outcomes and appeared to allow efficient use of health-care resources\(^ {31,45-51} \).

Institutions and practitioners may consider incorporating the following components into a standardized perioperative management protocol:

- Assessing patients at least 7 days before surgery to allow planning of perioperative anticoagulant management, especially before major surgery
- Providing patients and providers with a calendar outlining the perioperative timing of warfarin and antiplatelet drug discontinuation and resumption, dose and timing of LMWH bridging, and INR measurement schedule
- Ensuring that the perioperative management strategy (including timing of VKA and antiplatelet drug interruption and initiation and resumption of LWMH bridging) accounts for the drugs’ pharmacokinetic profile and patients’ thromboembolic and bleeding risks
- Ensuring patient and caregiver education on injection technique when outpatient LMWH bridging is administered
- INR testing on the day before surgery, where appropriate and feasible, to identify patients with elevated INRs and permit timely use of corrective oral vitamin K (1.0-2.5 mg), thereby avoiding blood product administration or surgery deferral\(^ {52} \)
- Assessing postoperative hemostasis, preferably on the day of surgery and on the first postoperative day, to facilitate safe resumption of anticoagulant drugs

**Cost-effectiveness of Perioperative Management Strategies**

The cost-effectiveness of bridging anticoagulation has been assessed using various decision analysis models\(^ {53-55} \). These studies suggest that for patients...
other than those at highest risk for stroke and ATE, bridging anticoagulation is unnecessary. In patients undergoing minor dental procedures, decision analyses have suggested that continuation of VKA therapy is less expensive than VKA interruption with bridging therapy. Studies of GI endoscopy have been consistent with American Society of Gastroenterology Guidelines, suggesting that continuing VKA therapy in patients having procedures associated with a low bleeding risk (eg, diagnostic endoscopy without biopsy) is less expensive than bridging, whereas discontinuation of VKA therapy without bridging is more cost-effective in patients at low thromboembolic risk who are undergoing high-bleeding-risk procedures. Prospective cohort studies have compared the costs of bridging anticoagulation with either in-hospital IV UFH or out-of-hospital SC LMWH. In one study comparing patient-administered SC LMWH, nurse-administered SC LWMH, and in-hospital IV UFH, the anticoagulant-related costs for patients having surgery with an overnight hospital stay were estimated at US $672, $933, and $3,916, respectively. Another cohort study comparing costs in 26 patients who received in-hospital IV UFH and 40 patients who received out-of-hospital SC LMWH and had elective surgery found a significantly lower mean total health-care cost (by $13,114) in patients who received perioperative LMWH. Taken together, these findings lead to questions about the need for bridging therapy in patients not considered at high risk for ATE. Furthermore, these studies confirm considerable cost savings with the use of SC LMWHs instead of IV UFH, which can be given in an outpatient setting by the patient or a family member in >90% of cases.

1.0 METHODS

1.1 Data Sources

The Medline English-language database was searched from January 1970 to January 2010 using multiple keywords and standardized terminology, where applicable, as outlined in Appendix S1. This search was done in two parts. The first was a systematic review of the literature from 1970 to January 2007, which was used in ATS. The second search updated this search strategy to include studies up until January 2010. We supplemented these literature searches by conducting Internet-based searches of ClinicalTrials.gov, meeting abstracts, and conference proceedings. In addition, reference lists of studies that satisfied inclusion criteria were manually reviewed. Finally, content experts were contacted to identify additional studies that were not identified by these search strategies.

1.2 Development of Chapter Recommendations and Narrative

The development of recommendations followed a prespecified process based on the following four steps: (1) developing PICO questions for clinical topics deemed important, which are summarized in Table 2; (2) identifying pertinent studies from ATS supplemented by additional searches of more recent studies; (3) developing provisional recommendations and parallel development of a draft manuscript and revision of original PICO questions; and (4) developing final recommendations by nonconflicted panelists. The development of article recommendations was guided by the topic editor (R. K.), whereas the development of the article narrative was overseen by the deputy editor (J. D.).

1.3 Development of Evidence Profiles, Summary of Findings Tables, and Recommendations

The recommendations in this article were developed in accordance with the methodologic changes in AT9 based on evidence profiles and summary of findings tables that followed the Grades of Recommendations, Assessment, Development, and Evaluation system format.

For the section on the perioperative management of VKA therapy, we developed evidence profiles to formulate recommendations for the prespecified PICO questions. These evidence profiles include studies directly pertinent to our PICO questions. Our recommendations were based on studies in the evidence profile that provided data specific to the perioperative clinical setting. In cases where there also were relevant studies from the nonperioperative setting, which were not part of the evidence profile because they provided indirect data, these studies also had a bearing on the recommendations. For the section on the perioperative management of antiplatelet therapy, evidence profiles were not produced in part because there were insufficient studies to develop profiles specific to the prespecified PICO questions. We produced summary of findings tables of all pertinent (but often indirect) data. The recommendations provided were based on the studies in these summary of findings tables, which are available in the online data supplement. As with the perioperative VKA management sections, additional studies may have been referenced in the narrative, but the recommendations were based entirely on studies in the summary of findings tables.

2.0 PERIOPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING VKA THERAPY

2.1 Interruption of VKAs Before Surgery

In patients undergoing major surgery or procedures, interruption of VKAs, in general, is required to minimize perioperative bleeding, whereas VKA interruption may not be required in minor procedures as discussed in subsequent sections of this article. Interruption of VKAs before surgery with the intent of achieving normal or near-normal hemostasis at the time of surgery is based on the residual pharmacodynamic effects of VKAs and the associated time required for the regeneration of vitamin K-dependent coagulation factors. This can be estimated by the elimination half-life of a VKA: 8 h for acenocoumarol, 36 to 42 h for warfarin, and 96 to 104 h for phenprocoumon. Assuming first-order pharmacokinetics, each half-life elapsed corresponds to an ~50% reduction in residual anticoagulant effect: 50% after one half-life, 25% after two half-lives, 12.5% after three half-lives, 6.25% after four half-lives, and 3.125% after five half-lives. For patients in whom the intent is to normalize the
### Table 2—[Section 1.2] Structured Clinical Questions

<table>
<thead>
<tr>
<th>Section</th>
<th>Population</th>
<th>Intervention and Comparator</th>
<th>Outcomes</th>
<th>Available Methodology</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Patients receiving warfarin therapy who require an elective surgery or invasive procedure</td>
<td>In patients who require warfarin interruption before surgery to attain normal or near-normal INR at surgery, stopping warfarin 5-6 d before surgery vs stopping warfarin &lt; 3 d before surgery</td>
<td>Hemostasis at time of surgery (INR)</td>
<td>Observational studies</td>
</tr>
<tr>
<td>2.2</td>
<td>In patients with warfarin interruption before surgery, resuming warfarin 12-24 h after surgery (evening of or next day) and when there is hemostasis vs resuming warfarin &gt; 24 h from surgery</td>
<td>Observational studies</td>
<td>Hemostasis at time of surgery</td>
<td>Observational studies</td>
</tr>
<tr>
<td>2.3</td>
<td>INR testing to monitor anticoagulant effect of warfarin before and after surgery vs no testing</td>
<td>Observational studies</td>
<td>Hemostasis at time of surgery (aPTT, antifactor Xa)</td>
<td>Observational studies</td>
</tr>
<tr>
<td>2.4</td>
<td>Need for bridging anticoagulation during perioperative warfarin interruption</td>
<td>Stroke, other systemic embolism, major hemorrhage</td>
<td>Observational studies</td>
<td></td>
</tr>
<tr>
<td>2.5</td>
<td>Patients considered at high risk for perioperative thromboembolism</td>
<td>Bridging anticoagulation with heparin/LMWH vs no bridging</td>
<td>Stroke, other systemic embolism, major hemorrhage</td>
<td>Observational studies</td>
</tr>
<tr>
<td></td>
<td>Patients considered at moderate risk for perioperative thromboembolism</td>
<td>Bridging anticoagulation with heparin/LMWH vs no bridging</td>
<td>Stroke, other systemic embolism, major hemorrhage</td>
<td>Observational studies</td>
</tr>
<tr>
<td></td>
<td>Patients considered at low risk for perioperative thromboembolism</td>
<td>Bridging anticoagulation with heparin/LMWH vs no bridging</td>
<td>Stroke, other systemic embolism, major hemorrhage</td>
<td>Observational studies</td>
</tr>
<tr>
<td>2.6</td>
<td>Patients having minor dental, skin, or eye procedures</td>
<td>Continuing warfarin and coadministering an oral prohemostatic drug vs stopping warfarin 5-6 d before the procedure without administering a prohemostatic drug</td>
<td>ATE or VTE, major hemorrhage</td>
<td>RCTs, observational studies</td>
</tr>
<tr>
<td>3.4</td>
<td>Patients receiving antiplatelet therapy and having minor dental, skin, or eye procedure</td>
<td>Continuing antiplatelet drugs around the time of the procedure vs stopping antiplatelet drugs 7-10 d before procedure</td>
<td>Myocardial ischemia, postoperative bleeding</td>
<td>Observational studies</td>
</tr>
<tr>
<td>3.5</td>
<td>Patients receiving antiplatelet therapy and having elective noncardiac surgery</td>
<td>Continuing antiplatelet drugs around the time of the procedure vs stopping antiplatelet drugs 7-10 d before noncardiac surgery</td>
<td>Myocardial ischemia, postoperative bleeding</td>
<td>RCTs, observational studies</td>
</tr>
<tr>
<td>3.6</td>
<td>Patients receiving antiplatelet therapy and having elective CABG surgery</td>
<td>Continuing antiplatelet drugs around the time of surgery vs stopping antiplatelet drugs 7-10 d before CABG</td>
<td>Myocardial ischemia, postoperative bleeding</td>
<td>Observational studies</td>
</tr>
</tbody>
</table>
### Table 2—Continued

<table>
<thead>
<tr>
<th>Section</th>
<th>Population</th>
<th>Intervention and Comparator</th>
<th>Outcomes</th>
<th>Available Methodology</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7</td>
<td>Patients with a coronary stent receiving antiplatelet therapy and having elective surgery</td>
<td>In patients with a bare-metal coronary stent who require surgery within 6 wk of stent placement or patients with a drug-eluting coronary stent who require surgery within 6 mo of stent placement, continuing antiplatelet drugs around the time surgery vs stopping antiplatelet drugs 7-10 d before surgery</td>
<td>Myocardial ischemia, postoperative bleeding</td>
<td>Observational studies</td>
</tr>
<tr>
<td>4.2</td>
<td>Patients who are receiving bridging anticoagulation with therapeutic-dose IV UFH</td>
<td>Stopping UFH 4-6 h before surgery vs stopping UFH closer to surgery</td>
<td>Postoperative bleeding</td>
<td>Observational studies</td>
</tr>
<tr>
<td>4.3</td>
<td>Patients who are receiving bridging anticoagulation with therapeutic-dose SC LMWH</td>
<td>Administering the last preoperative dose of LMWH ∼24 h before surgery vs administering the last preoperative dose of LMWH ∼12 h before surgery</td>
<td>Postoperative bleeding</td>
<td>Observational studies</td>
</tr>
<tr>
<td>4.4</td>
<td>Patients who are receiving bridging anticoagulation with therapeutic-dose SC LMWH</td>
<td>Resuming therapeutic-dose LMWH ≤24 h after surgery vs resuming LMWH &gt;24 h after surgery</td>
<td>Postoperative bleeding</td>
<td>Observational studies</td>
</tr>
</tbody>
</table>

**Abbreviations:** aPPT = activated partial thromboplastin time; ATE = arterial thromboembolism; CABG = coronary artery bypass graft; INR = international normalized ratio; LMWH = low-molecular-weight heparin; RCT = randomized controlled trial; SC = subcutaneous; UFH = unfractionated heparin.
INR after interruption of warfarin (half-life, 36-42 h), one would anticipate requiring at least 5 days for most anticoagulant effect to be eliminated after stopping warfarin. However, the decay of the anticoagulant effect of warfarin after interruption may not follow this pattern; for example, there may be delayed decay in elderly patients. For patients having minor procedures, where the anticipated bleeding is less, a shorter interval for VKA interruption may be sufficient whereby the aim is to attain an INR of 1.5 to 1.8 at the time of the procedure.

No randomized trials have directly compared the effects of early (5-6 days before surgery) vs delayed (<5 days before surgery) interruption of warfarin on perioperative bleeding outcomes (Table S1). (Tables that contain an “S” before the number and Appendices denote supplementary information not contained in the body of the article and available instead in an online data supplement; see the “Acknowledgments” for more information.) The only nonrandomized study addressing this issue is a retrospective case series of 21 patients who stopped warfarin 36 h prior to polypectomy and had a mean INR of 2.3 (range, 1.4-4.9) on the day of endoscopy. Although no patients developed major bleeding despite being given anticoagulants, all patients had endoscopic clips applied to the polyp stalks, which likely minimized any bleeding.

Most studies have assessed an early and delayed interruption of warfarin on a surrogate outcome of bleeding, namely the INR at the time of surgery. In the nonperioperative setting, a prospective cohort provides indirect evidence that a 5-day period of warfarin interruption is sufficient to allow decay of the anticoagulant effect and a normalization or near-normalization of the INR. In the perioperative setting, a prospective cohort study assessed 224 patients in whom warfarin was stopped 5 days before surgery and had INR testing on the day before surgery. This study found that only 15 patients (7%) had an INR >1.5 on the day of surgery, thereby supporting a 5-day interruption period before surgery to allow normalization of the INR. A retrospective case series that assessed delayed (2-3 days before procedure) interruption of warfarin did not allow sufficient time for normalization of the INR (mean INR at time of procedure, 1.8). Finally, in a randomized trial in which patients interrupted warfarin either 5 days or 1 day before surgery (with the latter group also receiving 1 mg vitamin K the day before surgery), the mean (95% CI) INR at the time of surgery was 1.24 (1.19-1.29) in the 5-day interruption group and 1.61 (1.50-1.71) in the 1-day interruption plus vitamin K group. Our recommendation, therefore, is based on the assumption that at the time of surgery, an elevated INR (ie, ≥2.0) will increase bleeding and a normal or near-normal INR (ie, <1.5) will not increase bleeding, with the caveat that there may be selected (usually minor) procedures that can be safely performed in patients managed with anticoagulant therapy. Additional study in this area is needed to better inform risks for bleeding in patients who continue or interrupt warfarin therapy.

**Recommendation**

2.1. In patients who require temporary interruption of a VKA before surgery, we recommend stopping VKAs approximately 5 days before surgery instead of stopping VKAs a shorter time before surgery (Grade 1C).

2.2. In patients who require temporary interruption of a VKA before surgery, we recommend resuming VKAs approximately 12 to 24 h after surgery (evening of or next morning) and when there is adequate hemostasis instead of later resumption of VKAs (Grade 2C).

**2.3 Perioperative Laboratory Monitoring of VKA Therapy**

Laboratory monitoring of VKA therapy with INR testing before surgery is intended to ensure normalization of the INR at surgery, which is important for patients who are receiving spinal/epidural anesthesia. No studies have assessed the effect of routine perioperative INR monitoring on health-care resource utilization, such as the need for blood products to reverse an excessive residual anticoagulant effect or deferral of surgery. Indirect evidence suggests that INR testing on the day before surgery will allow correction of elevated INRs with the potential to minimize blood product use or deferral of surgery.
study in which INR was routinely measured the day before surgery, 7% of patients had an INR > 1.5, which were all corrected with low-dose (1 mg) oral vitamin K. The use of vitamin K in this setting is also supported by a cohort study of 43 patients who had an INR of 1.5 to 1.9 on the day before surgery; administering 1 mg po vitamin K resulted in 39 patients (91%) having a normal or near-normal INR (≤1.4) on the day of surgery, with no surgeries cancelled.32

2.4 Need for Bridging Anticoagulation During Interruption of VKA Therapy

In patients with chronic atrial fibrillation, risk stratification for thrombotic events is based on the CHADS2 score because it is validated in a nonperiproperative setting, is widely used, and may be applicable in the perioperative setting25,26 (Table 1). In patients with a mechanical heart valve, the risk stratification is based on the position and type of valve. A high, moderate, or low risk for ATE and valve thrombosis refers to >10%/y, 5% to 10%/y, and <5%/y risks, respectively, in the absence of anticoagulation24,22 (Table 1). Finally, in patients with VTE, the risk stratification primarily depends on the time interval from the index VTE event to the surgery, and the distinction among high-, intermediate-, and low-risk groups is largely arbitrary28-30,76 (Table 1). This classification scheme has not been prospectively validated because data are lacking on risks for thromboembolism in the perioperative period when patients have interruption of VKA therapy and do not receive heparin bridging. Until such data are available, clinicians should consider this classification as an initial guide for decision-making that should be adapted to individual patient circumstances.

In observational studies, patients at high risk for thromboembolism have typically received bridging with therapeutic-dose SC LMWH (Table S2). This bridging regimen was associated with a low (1%-2%) incidence of ATE.31,45-47,51,79-85 Fewer, typically older, patients undergoing the following high-bleeding-risk procedures in whom no bridging therapy may be considered include the following:

• Carotid endarterectomy surgery
• Major cardiac surgery
• Carotid endarterectomy surgery

In addition, clinicians may consider using low-dose LMWH or UFH for VKA-treated patients with prior VTE because low-dose anticoagulation reduces the incidence of postoperative VTE in nonbridging clinical settings.86 For many patients whose indication for VKA therapy is prior VTE, low-dose LMWH or UFH is likely to achieve much of the benefit of therapeutic-dose anticoagulation while minimizing the risk of postoperative major bleeding, especially for patients undergoing major surgery. However, resumption of VKA therapy alone also may be considered as a method of prophylaxis against postoperative VTE.87

**Evidence profile:** There were no studies to match the associated PICO question, namely, studies limited
to or specific for patients at moderate risk for thromboembolism (Table S3).

Several studies assessed thromboembolic and bleeding outcomes of LMWH bridging with either a therapeutic-dose or a low-dose regimen in patients with atrial fibrillation, a mechanical heart valve, or VTE. However, there are other prospective and retrospective cohort studies in which patients with atrial fibrillation or VTE did not receive bridging. One prospective study assessed a no-bridging approach in low-risk patients with bileaflet aortic mechanical heart valves and no other major cardiovascular risks. The rate of ATE in low-risk patients who did not receive bridging appeared very low (<1%), thereby suggesting that bridging therapy may be unnecessary.

Recommendations

2.4. In patients with a mechanical heart valve, atrial fibrillation, or VTE at high risk for thromboembolism, we suggest bridging anticoagulation instead of no bridging during interruption of VKA therapy (Grade 2C).

Remarks: Patients who place a higher value on avoiding perioperative bleeding than on avoiding perioperative thromboembolism are likely to decline heparin bridging.

In patients with a mechanical heart valve, atrial fibrillation, or VTE at low risk for thromboembolism, we suggest no-bridging instead of bridging anticoagulation during interruption of VKA therapy (Grade 2C).

In patients with a mechanical heart valve, atrial fibrillation, or VTE at moderate risk for thromboembolism, the bridging or no-bridging approach chosen is, as in the higher- and lower-risk patients, based on an assessment of individual patient- and surgery-related factors.

2.5 Perioperative Management of VKA-Treated Patients Who Require Minor Procedures

Approximately 15% to 20% of all VKA-treated patients who are assessed for perioperative anticoagulant management require minor dental, dermatologic, or ophthalmologic procedures. Because these procedures, in general, are associated with relatively little blood loss or self-limiting blood loss that is controlled with local hemostatic measures, this section focuses on whether VKA therapy can be safely continued in the periprocedural period. Although we indicate that these procedures are minor and bleeding that occurs may not result in serious bleeding, such occurrences, nevertheless, may be important to patients if it engenders anxiety and distress. For patients having dental, skin, or eye procedures that are associated with a higher risk for bleeding, such as reconstructive dental or plastic surgery or vitreoretinal surgery, in which interruption of VKA therapy is required, bridging anticoagulation can be considered (as with other major surgeries and procedures) but is addressed in section 4.0 of this article.

Minor dental procedures assessed include tooth extractions and endodontic (root canal) procedures (Table S4). Many randomized trials and prospective cohort studies have assessed periprocedural anticoagulant management in VKA-treated patients undergoing minor dental procedures (Table S5). Despite the extent of study in this area, one problem in identifying a single optimal practice is that several different management strategies have been assessed, including continued VKA in the peridental period with or without coadministered prohemostatic interventions (eg, antifibrinolytic drugs, sutures), partial (2-3 days before procedure) VKA interruption, and complete (5-6 days before procedure) VKA interruption. Among these management approaches, perhaps the most relevant question is whether VKAs can be safely continued in the peridental period, especially if an oral antifibrinolytic drug (tranexamic acid mouthwash) is coadministered. One randomized trial compared continuing VKA therapy with or without tranexamic acid; other trials compared continuing VKAs with tranexamic acid against other strategies, such as interruption of VKAs 3 or 5 days before the procedure. Prospective cohort studies have assessed continuing VKAs with tranexamic acid.

Taken together, these studies suggest that continuing VKAs with a prohemostatic agent is associated with a low (<5%) risk for clinically relevant nonmajor bleeding. If tranexamic acid is used, it is given as a 5-mL oral dose, 5 to 10 min before the dental procedure and 3 to 4 times daily for 1 to 2 days after the procedure. Another approach associated with a low risk for bleeding, based on findings from prospective cohort studies, is partial interruption of VKA therapy for 2 to 3 days before a dental procedure, which would result in an INR of 1.6 to 1.9 on the day of the procedure.

Overall, the available studies suggest that two approaches—VKA continuation with a prohemostatic agent or partial (2-3 days) VKA interruption—confers a low risk for bleeding. Nonetheless, minor bleeding (oozing from gingival mucosa) may be more common with these approaches than complete VKA interruption. Patients should be informed of this outcome and of the need to continue tranexamic acid use and to apply local pressure to stop such bleeding. Thromboembolic outcomes are rare (<0.1%), although
prior studies were underpowered to detect relative and absolute differences in thromboembolic events occurring in association with different interventions.

Minor dermatologic procedures assessed include excision of basal and squamous cell skin cancers, actinic keratoses, and premalignant or cancerous skin nevi.139 No randomized trials have assessed perioperative management. Prospective, controlled cohort studies noted a more than threefold higher incidence of nonmajor and minor bleeding in patients who continued VKA therapy compared with patients who had VKA interruption (Table S6).120-123 Most of these bleeding episodes reported were self-limiting. The incidence of major bleeding with periprocedural continuation of VKAs appears to be low (<5%), although these studies may have been underpowered to detect an increase in major bleeding.

Cataract extraction is largely an avascular procedure, and prospective cohort studies124-135 have reported an incidence of clinically important bleeding of <3% (Table S7). In a meta-analysis of observational studies of VKA-treated patients undergoing cataract surgery, patients who continued VKA had an increased risk for bleeding (OR, 3.26; 95% CI, 1.73-6.16) with an overall incidence of bleeding of 10% (95% CI, 5-19).35 Almost all bleeds were self-limiting, consisting of dot or subconjunctival bleeds, and no patient had compromised visual acuity related to bleeding.

An important consideration is the safety of retrobulbar anesthesia in patients who are given anticoagulants and are also undergoing cataract surgery given the potential that without prompt orbital decompression, retrobulbar hematoma may lead to vision loss. The available data suggest that such bleeds are uncommon, occurring in fewer than one per 100 procedures,126 irrespective of whether a patient is receiving a VKA. An alternative approach that also appears safe during VKA therapy is a phacoemulsification technique under topical anesthesia.135

Recommendation

2.5. In patients who require a minor dental procedure, we suggest continuing VKAs with coadministration of an oral prohemostatic agent or stopping VKAs 2 to 3 days before the procedure instead of alternative strategies (Grade 2C). In patients who require minor dermatologic procedures and are receiving VKA therapy, we suggest continuing VKAs around the time of the procedure and optimizing local hemostasis instead of other strategies (Grade 2C). In patients who require cataract surgery and are receiving VKA therapy, we suggest continuing VKAs around the time of the surgery instead of other strategies (Grade 2C).

3.0 Perioperative Management of Patients Who Are Receiving Antiplatelet Drugs

3.1 Interruption of Antiplatelet Drugs Before Surgery

Antiplatelet drugs that irreversibly inhibit platelet function—making their short half-lives clinically irrelevant—including ASA, clopidogrel, ticlopidine, and prasugrel.136 For each day after interruption of any of these agents, ~10% to 14% of normal platelet function is restored; later, it takes 7 to 10 days for an entire platelet pool to be replenished.137,138 Antiplatelet drugs that reversibly inhibit platelet function, with self-limiting effects depending on their elimination half-lives, include dipyridamole, cilostazol, and nonsteroidal antiinflammatory drugs. Dipyridamole, a pyridopyrimidine derivative with antiplatelet and vasodilator properties, has a half-life of 10 h, but because it is typically combined with ASA, this nullifies its reversible antiplatelet effect.139 Cilostazol, a phosphodiesterase inhibitor with antiplatelet and vasodilator properties, has a half-life of 10 h.140 Nonsteroidal antiinflammatory drugs have half-lives that vary from 2 to 6 h (ibuprofen, ketoprofen, indomethacin), to 7 to 15 h (celecoxib, naproxen, diflunisal), to >20 h (meloxicam, nabumetone, piroxicam).141

No randomized trials have assessed the optimal timing of antiplatelet drug interruption before surgery, in particular, whether stopping 7 to 10 days before surgery (to allow complete elimination of the antiplatelet effect) or closer to surgery affects bleeding and thromboembolic outcomes. Cohort studies involving patients who were receiving a VKA combined with ASA typically stopped ASA 7 to 10 days before surgery, although many of these patients also received LMWH bridging during VKA interruption.45-47

3.2 Resumption of Antiplatelet Drugs After Surgery

When resuming ASA, the maximal antiplatelet effect occurs within minutes, whereas with resumption of clopidogrel at a maintenance dose (75 mg/d), it takes 5 to 10 days to attain maximal platelet function inhibition.142 With a clopidogrel loading dose (300-600 mg/d), maximal platelet function inhibition is attained within 12 to 15 h after administration.143,144 Cohort studies involving patients who were receiving a VKA and ASA typically resumed ASA at the same time as the VKA, which was within 24 h after surgery in most patients.45-47

3.3 Laboratory Monitoring of Antiplatelet Therapy

Several platelet function assays are available to measure the antiplatelet effect of ASA and clopidogrel and have been assessed primarily in patients...
having cardiac surgery or percutaneous coronary interventions. However, the clinical significance of assay findings is uncertain, and the assay results have not been shown to predict clinical outcomes. Additional study is needed, especially in patients having noncardiac surgery, before these assays can be considered for use in clinical practice.

3.4 Patients Having a Minor Dental, Dermatologic, or Ophthalmologic Procedure

In patients having dental procedures, several small studies (<100 patients) comprising randomized trials and cohort studies suggested no increase in major bleeding with ASA continuation. Only one 43-patient retrospective cohort study assessed the safety of dental procedures in 29 patients receiving combined ASA and clopidogrel and found no bleeding episodes with continuation of dual antiplatelet therapy.

In patients having minor skin procedures, several prospective cohort studies, including ~200 patients, suggested a very-low (<1%) risk for major bleeding with continuation of ASA. These studies also suggested an increase in minor bleeding with ASA continuation compared with controls who were not receiving antithrombotic therapy, but the incidence rates varied widely (2%-51%), likely reflecting different thresholds for defining minor bleeding. Nonetheless, these findings are consistent with those in patients who continued VKAs around minor skin procedures and indicate the need for adequate attention to postprocedure hemostasis.

Among patients undergoing cataract surgery, prospective cohort studies have suggested a low (<1%) incidence of major bleeding with perioperative continuation of ASA. The incidence of cardiovascular events in one cohort study was similar in patients who continued or interrupted ASA (0.20% vs 0.65%), although a distinction was not made according to patient clinical indication for ASA therapy. No studies assessed the management of patients who receive clopidogrel alone and require minor dental, skin, or eye procedures.

Recommendation

3.4. In patients who are receiving ASA for the secondary prevention of cardiovascular disease and are having minor dental or dermatologic procedures or cataract surgery, we suggest continuing ASA around the time of the procedure instead of stopping ASA 7 to 10 days before the procedure (Grade 2C).

3.5 Patients Having Noncardiac Surgery

Several studies assessed the effects of ASA continuation or interruption before surgery (Table S8). Indirect evidence is available from a 19,000-patient placebo-controlled trial (Pulmonary Embolism Prevention trial) that compared de novo low-dose ASA use started before hip fracture repair or joint replacement surgery and continued for 35 days after surgery. ASA use was associated with a possible increase in clinically recognized myocardial infarction (risk ratio, 1.57; 95% CI, 0.93-2.65) but failed to demonstrate a reduction or increase in stroke (risk ratio, 1.13; 95% CI, 0.69-1.85). Although this study was done in the pretroponin era, effects of ASA therapy on clinically silent myocardial ischemia or stroke cannot be excluded. Furthermore, patients were not limited to those at risk for acute coronary events because the trial was intended to determine the effect of ASA on postoperative prevention of VTE. Perioperative ASA use conferred a small increase in the risk for major bleeding (2.9% vs 2.4%, P = .04) and, indeed, decreased the risk for postoperative VTE (risk ratio, 0.71; 95% CI, 0.54-0.94).

A small randomized trial is unique in that it involved patients at high risk for cardiovascular events who were undergoing noncardiac surgery and who started ASA (75 mg once daily) or placebo 7 days before surgery and continued it for 30 days after surgery. This study found that perioperative ASA use conferred a significant reduction in myocardial infarction and other major cardiovascular events (1.8% vs 9.0%, P = .02), but the study was underpowered to detect differences in bleeding outcomes. A meta-analysis of >49,000 patients who had noncardiac surgery, of whom 15,000 were receiving long-term ASA prior to surgery, found that perioperative continuation of ASA increased the overall risk for bleeding (risk ratio, 1.5; interquartile range, 1.0-2.5) but did not increase bleeding requiring a medical intervention. However, patients requiring intracranial or prostate surgery did have an increase in bleeding with perioperative ASA continuation, and in such patients (and others deemed at high risk for bleeding), perioperative continuation of ASA should be considered with caution. This meta-analysis did not report on cardiovascular outcomes. Taken together, these data suggest that patients with coronary artery or other cardiovascular disease, who may be considered at moderate to high risk for perioperative adverse cardiovascular events, may benefit from perioperative continuation of ASA. Such moderate-to-high-risk patients include those with ischemic heart disease, compensated or prior congestive heart failure, diabetes mellitus, renal insufficiency, or cerebrovascular disease. In addition, patients undergoing selected types of surgery associated with an increased risk for perioperative cardiovascular events, such as carotid endarterectomy and peripheral artery
bypass surgery, may also benefit from perioperative continuation of ASA.\textsuperscript{162-164} In patients considered at low risk for cardiovascular events in whom there is likely to be fewer potential benefits of perioperative continuation of ASA, interruption of ASA may be reasonable.

Few studies assessed perioperative continuation of clopidogrel. These studies, all of which were retrospective cohort analyses, suggested increased rates of bleeding with perioperative or periprocedural clopidogrel continuation.\textsuperscript{165-167} Indirect data from a linked database involving patients in the nonoperative setting indicate that clopidogrel-only users are at 33\% higher risk for bleeding than ASA-only users (risk ratio, 1.33; 95\% CI, 1.11-1.59),\textsuperscript{168} thereby implying that the antiplatelet potency of clopidogrel is greater than that of ASA. This finding appears to support anecdotal observations of clinicians (including the article panelists) involved in perioperative antithrombotic management because there appears to be a higher bleeding tendency in patients continuing clopidogrel than in those continuing ASA perioperatively. Although clopidogrel appears to confer less GI bleeding than ASA in the nonoperative setting,\textsuperscript{169} this decreased tendency for bleeding may be related to less GI irritation with clopidogrel and may not be applicable to the perioperative setting.

Recommendation

3.5. In patients at moderate to high risk for cardiovascular events who are receiving ASA therapy and require noncardiac surgery, we suggest continuing ASA around the time of surgery instead of stopping ASA 7 to 10 days before surgery (Grade 2C). In patients at low risk for cardiovascular events who are receiving ASA therapy, we suggest stopping ASA 7 to 10 days before surgery instead of continuation of ASA (Grade 2C).

3.6 Patients Having Coronary Artery Bypass Graft Surgery

Most patients who require a coronary artery bypass graft (CABG) are receiving long-term ASA therapy. In addition, 10\% to 15\% of patients who have had an acute coronary syndrome will require urgent CABG surgery and are, typically, receiving both ASA and clopidogrel/prasugrel.\textsuperscript{170} The issue of whether antiplatelet drugs should be continued or stopped is important because of the need to minimize perioperative bleeding, especially mediastinal bleeding that can cause pericardial tamponade. In a > 11,000-subject cohort study of patients undergoing CABG, packed red cell transfusion (which occurred in 49\% of patients) conferred an increased risk for mortality (risk ratio, 1.77; 95\% CI, 1.67-1.87) as well as renal failure and neurological events.\textsuperscript{171} Other observational studies have shown an increased risk for bleeding with perioperative ASA use in patients having CABG.\textsuperscript{172,173} A meta-analysis of studies assessing perioperative continuation of ASA confirmed an increase in postoperative bleeding (as measured by chest tube drainage) but no increase in the need for reoperation.\textsuperscript{174} Against these potential bleeding risks, ASA use within 5 days prior to CABG surgery was associated in a > 8,000-patient cohort study to reduce overall mortality without a concomitant increased risk for reoperation for perioperative bleeding or need for blood transfusion.\textsuperscript{43} Other smaller observational studies have also found a reduction in cardiovascular events and overall mortality in patients who continue ASA prior to CABG surgery.\textsuperscript{175,176} Taken together, it appears that although ASA increases the risk for postoperative bleeding, there is no increased risk for reoperation, which is coupled with the potential for decreased cardiovascular events and overall mortality. However, given the uncertainty in the relative risks and benefits of perioperative ASA continuation, clinicians may individualize patient management; for example, it may be reasonable to stop ASA in patients with stable coronary artery disease who require CABG.

With the common use of thienopyridine derivatives, such as clopidogrel, in patients who require CABG, the issue of how to manage ASA and clopidogrel around the time of CABG surgery is clinically relevant. Subgroup analyses of large trials involving patients with an acute coronary syndrome who were receiving dual antiplatelet therapy (ASA and clopidogrel) and who subsequently needed CABG found a 50\% higher incidence in major bleeding and a 70\% higher incidence of transfusion requirements in those who received clopidogrel within the 5-day period before CABG, but this risk appears to be minimized if clopidogrel is stopped at least 5 days before CABG surgery.\textsuperscript{177,178} Observational studies also found increased bleeding in patients exposed to clopidogrel within 5 days of CABG surgery.\textsuperscript{179-181} For patients who are receiving dual ASA-clopidogrel therapy in whom urgent CABG surgery is required and a 5-day or longer delay after clopidogrel interruption is not feasible, a probable increase in bleeding risk should be anticipated. Options to reduce bleeding transfusion requirements include preoperative platelet transfusion and administering antifibrinolytic drugs such as tranexamic acid or e-aminocaproic acid\textsuperscript{182,183} but not aprotinin,\textsuperscript{184} which confers an increased risk for thrombotic and other adverse events.

Recommendation

3.6. In patients who are receiving ASA and require CABG surgery, we suggest continuing...
ASA around the time of surgery instead of stopping ASA 7 to 10 days before surgery (Grade 2C). In patients who are receiving dual antiplatelet drug therapy and require CABG surgery, we suggest continuing ASA around the time of surgery and stopping clopidogrel/prasugrel 5 days before surgery instead of continuing dual antiplatelet therapy around the time of surgery (Grade 2C).

3.7 Patients With Coronary Stents Having Surgery

The management of patients with coronary stents who require surgery is a common and challenging clinical problem. One retrospective-linked database study of 17,797 stented patients found that 11% of patients required surgery during a 2-year period after stent placement and that 4% required surgery within 1 year of stent placement.185

Patient management is problematic because of concerns about the incidence and clinical consequences of stent-related coronary thrombosis if antiplatelet therapy is interrupted. In the nonoperative setting, observational studies and case reports of suboptimal methodological quality have suggested a markedly increased risk for stent thrombosis after premature antiplatelet drug interruption and after temporary interruption of treatment because of surgery.186-191 In several retrospective studies totaling >2,200 patients who had surgery within 2 years of stent placement, the incidence of postoperative stent thrombosis was, on average, between 2% and 5%.192-197 Moreover, these studies suggested that the clinical impact of stent thrombosis and associated coronary events is considerable, with case-fatality rates of ≥50%.

Despite concerns about the extent and severity of perioperative thrombotic events in patients with coronary stents, there are no randomized trials comparing different perioperative management strategies. Furthermore, in observational studies of stented patients who had surgery, outcome events generally were not reported according to a prespecified intervention, such as whether patients had perioperative interruption of dual antiplatelet therapy (ASA and clopidogrel/prasugrel), interruption of a single agent, or continuation of dual antiplatelet therapy. Consequently, conclusions are limited about optimal perioperative management.

Indirect evidence from the nonperioperative clinical setting indicates that premature discontinuation of dual antiplatelet therapy, within 6 weeks of bare-metal stent placement or within 3 to 6 months of drug-eluting stent placement, increases the risk for stent thrombosis and appears to be the strongest predictor of stent thrombosis.198 On the other hand, in patients who require CABG, perioperative continuation of dual antiplatelet therapy confers an increased risk for bleeding, which includes life-threatening pericardial tamponade. What is unclear is whether there is a similarly increased risk for serious bleeding with perioperative continuation of dual antiplatelet therapy in patients having noncardiac surgery and procedures. Overall, there is substantial uncertainty about whether the potential benefits of continuing dual antiplatelet therapy outweigh the likely increased risk for bleeding.

The role of bridging therapy in patients with coronary stents who require elective surgery is uncertain. Only a few case reports assessed the use of short-acting antithrombotic drugs such as UFH, LMWHs, or glycoprotein IIb/IIIa antagonists (eg, tirofiban, epifibatide) in the perioperative setting.199-201 Reversible platelet P2-receptor inhibitors, such as ticagrelor, may play a role as bridging therapy in this clinical setting. Studies are needed to assess the role of bridging therapy, if any, in patients who are receiving antiplatelet drugs. Until such data are available, the use of short-acting antithrombotic agents in patients who require temporary interruption of antiplatelet therapy is inadvisable.

Recommendation

3.7. In patients with a coronary stent who are receiving dual antiplatelet therapy and require surgery, we recommend deferring surgery for at least 6 weeks after placement of a bare-metal stent and for at least 6 months after placement of a drug-eluting stent instead of undertaking surgery within these time periods (Grade 1C). In patients who require surgery within 6 weeks of placement of a bare-metal stent or within 6 months of placement of a drug-eluting stent, we suggest continuing dual antiplatelet therapy around the time of surgery instead of stopping dual antiplatelet therapy 7 to 10 days before surgery (Grade 2C).

Remarks: Patients who are more concerned about avoiding the unknown, but potentially large increase in bleeding risk associated with the perioperative continuation of dual antiplatelet therapy than avoiding the risk for coronary stent thrombosis are unlikely to choose continuation of dual antiplatelet therapy.

4.0 Perioperative Management of Patients Who Are Receiving Heparin Bridging Anticoagulation

4.1 Anticoagulants and Anticoagulant Dose Regimens Considered for Bridging

There is no established single heparin bridging regimen. Variability exists in the type of anticoagulant...
(LMWH or UFH), intensity of anticoagulation (therapeutic dose, low dose, or intermediate dose), and timing of perioperative administration. In considering which regimen and administration approach to use, there are several points to consider:

• **Anticoagulant intensity to prevent thromboembolism.** In the absence of randomized trials assessing the efficacy of different intensities of bridging regimens to prevent ATE, including stroke, we have used indirect data. First, although evidence is lacking that LMWHs prevent recurrent stroke, indirect data from a large trial investigating idraparinux (a synthetic factor Xa inhibitor with similar anticoagulant properties as LMWHs) found it to be as effective as warfarin for stroke prevention in patients with atrial fibrillation, thereby supporting the use of therapeutic-dose LMWH for perioperative stroke prevention. Second, although low-dose LMWH or UFH is effective to prevent VTE after surgery, evidence is lacking about whether such low-dose heparin regimens are effective in preventing ATE, including stroke. Lower-dose VKA regimens (target INR < 2.0), which might be considered comparable to low-dose heparin regimens, are less effective for stroke prevention.

• **Proximity to surgery of anticoagulant administration and risk for bleeding.** From randomized trials assessing different anticoagulant regimens for postoperative VTE prophylaxis, there is consistent evidence that the closer to surgery an anticoagulant is given, the higher the risk for bleeding. Thus, bleeding is greater when a first dose is given early (4-8 h postoperatively), lower when given at an intermediate interval (12-24 h postoperatively), and lowest when administration is delayed for >24 h postoperatively. Clinicians should assess postoperative hemostasis and determine whether wound-site hemostasis has occurred and the surgical bed is dry. Although subjective, this can be aided by assessing the amount, type (serous, serosanguinous, bloody), and progress (continuing, increasing, decreasing) of drainage and blood collection in wound bandages or surgical drains. Heparin bridging, especially a therapeutic-dose regimen, should be delayed after surgery until there is adequate hemostasis.

• **Dose of anticoagulant administration and risk for bleeding.** One observational study suggested that use of a higher-intensity therapeutic-dose bridging regimen may be associated with a more than fourfold risk (OR, 4.4; 95% CI, 1.5-14.7) for postoperative major bleeding compared with a low-dose regimen. This finding is consistent with studies assessing the intensity of anticoagulant therapy for the secondary prevention of VTE and stroke. Other observational studies suggested that a once-daily therapeutic-dose bridging regimen may be associated with a higher risk for bleeding than a bid (split-dose) therapeutic-dose regimen, but direct comparisons of once-daily vs bid heparin bridging regimens have precluded definitive conclusions. Taken together, these findings suggest caution in using higher-intensity therapeutic-dose heparin bridging after surgery, especially in patients undergoing high-bleeding-risk surgery and procedures.

Based on these considerations, we suggest the following two guides for postoperative management of bridging anticoagulation:

1. LMWH or UFH should not be resumed at a fixed time after a surgery or procedure without consideration of the anticipated bleeding risk or adequacy of postoperative hemostasis.

2. If therapeutic-dose bridging is used in patients at high risk for postoperative bleeding, its initiation should be delayed for 48 to 72 h after surgery when adequate surgical hemostasis has been achieved. If bleeding continues beyond 72 h, options include a low-dose heparin bridging regimen or VKA resumption alone without postoperative bridging.

### 4.2 Perioperative Use of IV UFH

IV UFH administered to achieve an aPTT of 1.5 to 2.0 times the control aPTT is an option for perioperative bridging. UFH may be of particular use in, for example, patients with severe renal insufficiency or dependency on dialysis in whom LMWHs should be avoided. No studies have assessed the timing of interruption of IV UFH. However, the dose-dependent elimination half-life of 90 min (range, 30-120 min) suggests that an infusion can be stopped 4 to 6 h before surgery. Resumption of IV UFH after surgery should follow the approach used for SC LMWH, with IV UFH resumed without a bolus dose at the same infusion rate as that used preoperatively.

Bridging anticoagulation with UFH may be considered for out-of-hospital administration using a fixed-dose, weight-based, SC regimen (250 International Units/kg bid) that does not require aPTT monitoring.

**Recommendation**

**4.2. In patients who are receiving bridging anticoagulation with therapeutic-dose IV UFH, we**
suggest stopping UFH 4 to 6 h before surgery instead of closer to surgery (Grade 2C).

4.3 Preoperative Interruption of Therapeutic-Dose Bridging LMWH

In observational studies assessing LMWH bridging, there were no apparent higher bleeding rates (compared with nonbridged controls from other studies) if the last dose of LMWH was given ∼12 h (ie, the evening) before surgery or ∼24 h before surgery.45,46 However, in studies assessing a surrogate marker for bleeding (antifactor Xa levels), >90% of patients who received their last LMWH dose ∼12 h before surgery had a detectable anticoagulant effect at surgery, with 34% of patients having a therapeutic level of anticoagulation (ie, antifactor Xa ≥0.50 International Units/mL) at surgery.211,212 Although these studies could not assess the effect of residual anticoagulation on bleeding outcomes, clinicians should consider withholding the last LMWH dose before surgery when a bid regimen is used and giving half the total dose the morning before surgery when a once-daily regimen is used to minimize the residual anticoagulant effect at the time of surgery.

Recommendation

4.3. In patients who are receiving bridging anticoagulation with therapeutic-dose SC LMWH, we suggest administering the last preoperative dose of LMWH approximately 24 h before surgery instead of 12 h before surgery (Grade 2C).

4.4 Postoperative Resumption of Therapeutic-Dose Bridging LMWH

An observational study in which all patients received LMWH (1.5 mg/kg) started 12 to 24 h after all types of surgery, patients who had major (>1 h duration) surgery had a 20% (8/40) incidence of major bleeding, whereas major bleeding occurred in 0.7% (1/148) in patients who had a minor (<1 h duration) surgery or procedure.19 In other observational studies assessing therapeutic-dose LMWH bridging, an indirect, across-study comparison yielded an apparent lower risk for nonmajor bleeding with delayed resumption of LMWH. Other observational studies that allowed a flexible postoperative bridging regimen in high-bleeding-risk patients with either delayed resumption of therapeutic-dose LMWH or substitution of a low-dose regimen found a low incidence of major bleeding (<5%).31,47-49,51,85,213,214 Taken together, these studies suggest that the resumption of LMWH should be delayed for at least 24 h and probably longer (48-72 h) in patients undergoing major surgery, with resumption contingent on clinical evidence of surgical-site hemostasis. In studies that assessed moderate- or low-bleeding-risk patients who received therapeutic-dose LMWH started approximately 24 h after surgery (on the morning of the day after surgery), the incidence of major and nonmajor bleeding was low (<3%).45-47

Recommendation

4.4. In patients who are receiving bridging anticoagulation with therapeutic-dose SC LMWH and are undergoing high-bleeding-risk surgery, we suggest resuming therapeutic-dose LMWH 48 to 72 h after surgery instead of resuming LMWH within 24 h after surgery (Grade 2C). In patients who are receiving bridging anticoagulation with therapeutic-dose SC LMWH and are undergoing non-high-bleeding-risk surgery, we suggest resuming therapeutic-dose LMWH approximately 24 h after surgery instead of resuming LMWH more than 24 h after surgery.

5.0 Research Recommendations

Additional research is necessary to establish best practices for patients who are receiving antithrombotic therapy and require surgery. Efforts to bridge these gaps in knowledge are ongoing. The randomized placebo-controlled trials PERIOP-2 (A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin),215 BRIDGE (Effectiveness of Bridging Anticoagulation for Surgery),216 PACEBRIDGE (Preoperative Low Molecular Weight Heparin vs Tapered Warfarin as Bridging Therapy for patients with Implantation of Pacemaker or Defibrillator), and BRUISECONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial)217 are assessing the need for LMWH bridging in VKA-treated patients. POISE-2 (PeriOperative Ischemic Evaluation-2 Trial)218 is a placebo-controlled trial assessing the perioperative continuation or interruption of ASA in patients undergoing noncardiac surgery, and ATACAS (Aspirin and Tranexamic Acid for Coronary Artery Surgery Trial) (ACTR [Australian Clinical Trials Registry] No. 1260500557639) is assessing perioperative use of ASA in patients undergoing CABG surgery.219 Large observational studies are planned to assess best perioperative practices in patients who are receiving new oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, and new antiplatelet drugs, such as prasugrel and ticagrelor. Additional research is needed to inform best perioperative practices in special populations (obese, renal insufficiency) and, especially, in patients with coronary stents.
ACKNOWLEDGMENTS

Author contributions: As Topic Editor, Dr Kunz oversaw the development of this article, including the data analysis and subsequent development of the recommendations contained herein.

Dr Douketis: contributed as Deputy Editor for this topic.

Dr Spyropoulos: contributed as a panelist.

Dr Spencer: contributed as a panelist.

Dr Mayr: contributed as a frontline clinician.

Dr Jaffer: contributed as a panelist.

Dr Eckman: contributed as a resource consultant.

Dr Dunn: contributed as a panelist.

Dr Kunz: contributed as Topic Editor for this section.

Financial/nonfinancial disclosures: The authors of this guide provided detailed information related to each individual recommendation made in this article. A grid of these disclosures is available online at http://chestjournal.chestpubs.org/content/141/2_suppl/e326S/suppl/DC1. In summary, the authors have reported to CHEST the following conflicts of interest: Dr Douketis was a consultant for Boehringer-Ingelheim and served as a consultant during four advisory board meetings (by Sanofi-Aventis, Astra-Zeneca, Boehringer-Ingelheim, Pfizer) relating to the development and clinical use of novel, but not approved for clinical use, antiplatelet drugs (ticagrelor) and anticoagulant drugs (apixaban, semuloparin, dabigatran).

Dr Eckman has received the following university grants: “Using Decision Analytic Modeling to Guide the ACCP Guideline Development Process for Antithrombotic Therapy in Atrial Fibrillation” (Foundation for Informatics Medical Decision Making; October 2011-September 2013; $185,000); “Cost-Effectiveness of Screening for Chronic Hepatitis C Infection” (Merck/Schering-Plough; October 2011-September 2012; $58,000); “Greater Cincinnati BEACON Collaborative” (Office of the National Coordinator for Health Information Technology [90BC0016/01]; September 2010-March 2012; ~15% effort); “Cincinnati Center for Clinical and Translational Science and Training (CTSA) ARIA Supplement for Development of Distance Learning Program in Medical Informatics” (National Institutes of Health [NIH]/National Center for Research Resources [NCRR] [UL1 RR026314-01]; August 2009-August 2011; ~20% effort); “Cincinnati Center for Clinical and Translational Science and Training (CTSA)” (NIH/NCRR [1U54 RR 025216]; January 2009-February 2014; ~15% effort); “A Patient Specific Decision Support Tool for Bariatric Surgery” (National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK075599]; August 2007-June 2012; no financial support); National Heart, Lung, and Blood Institute [K23 HL085387; June 2008-March 2013; no financial support]; and “Cost-Effectiveness of Screening for Chronic Hepatitis B Infection” (Gilead Sciences Inc; March 2008-August 2010; ~$56,000). He has also served as consultant for Savient Pharmaceuticals (“Cost Effectiveness Analysis of Gout Medication”; 2010; ~$300) and as editorial consultant for the ACP (“Physicians’ Information and Education Resource [PIER]: Module on Pre-Operative Assessment for Bleeding Disorders”; 2006-present; ~$250/year).

Dr Spyropoulos has served as a consultant to Pfizer, Sanofi-Aventis, and EISAI. Dr Jaffer served as a consultant to sanofi-aventis, Jansen, Canyon Pharmaceuticals, Boehringer Ingelheim, and Daiichi Sankyo; he has formerly spoken on behalf of sanofi-aventis. Dr Jaffer is also on the steering committee of an NHLBI clinical trial, Dr Kunz is a member of the GRADE Working Group, the methodology of which is used in these guidelines. She has an interest in seeing this methodology applied. Drs Spencer, Mayr, and Dunn have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Role of sponsors: The sponsors played no role in the development of these guidelines. Sponsoring organizations cannot recommend panelists or topics, nor are they allowed prepublication access to the manuscripts and recommendations. Guideline panel members, including the chair, and members of the Health & Science Policy Committee are blinded to the funding sources. Further details on the Conflict of Interest Policy are available online at http://chestjournal.chestpubs.org.

Endorsements: This guideline is endorsed by the American Association for Clinical Chemistry, the American College of Clinical Pharmacy, the American Society of Health-System Pharmacists, the American Society of Hematology, and the International Society of Thrombosis and Hemostasis.

Other contributions: Deborah Siegel, MD, contributed to the generation of the evidence profiles for the recommendations 2.4 and 4.2-4.4.

Additional information: The Appendix S1 and supplement Tables can be found in the Online Data Supplement at http://chestjournal.chestpubs.org/content/141/2_suppl/e326S/suppl/DC1.

REFERENCES


84. Constans M, Santamaria A, Mateo J, Pujol N, Souto JC, Fontcuberta J. Low-molecular-weight heparin as bridging...


120. Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively.
160. Poldermans D, Bax JJ, Boersma E, et al; Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of European Society of Cardiology (ESC); European Society of Anaesthesiology.


© 2012 American College of Chest Physicians
Perioperative Management of Antithrombotic Therapy

Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

James D. Douketis, MD, FCCP; Alex C. Spyropoulos, MD, FCCP; Frederick A. Spencer, MD; Michael Mayr, MD; Amir K. Jaffer, MD, FHM; Mark H. Eckman, MD; Andrew S. Dunn, MD; and Regina Kunz, MD, MSc (Epi)

APPENDIX S1 — MEDLINE LITERATURE
SEARCH STRATEGY

1. Anticoagulants/ or perioperative anticoagulation.mp.
2. warfarin.mp. or exp Warfarin/
3. exp Heparin/ or exp Heparin, Low-Molecular-Weight/ or heparin.mp.
4. exp Perioperative Care/ or perioperative.mp.
5. atrial fibrillation.mp. or exp Atrial Fibrillation/
6. exp Heart Valve Prosthesis/ or mechanical heart valve.mp.
7. exp Thrombosis/ or thrombosis.mp. or exp Venous Thrombosis/
8. 4 or 1
9. 8 and 7 and 2
10. 3 and 9
11. 9 and 5
12. 8 and 6
13. aspirin.mp. or exp Aspirin/
14. antiplatelet agent.mp. or exp Platelet Aggregation Inhibitors/
15. 13 or 14
16. 4 and 15
Table S1—[Section 2.1] Evidence Profile: PICO in Patients Who Require Warfarin Interruption Before Surgery to Attain Normal or Near-Normal INR At Surgery, Stopping Warfarin 5 to 6 Days Before Surgery vs Stopping Warfarin < 5 d Before Surgery

<table>
<thead>
<tr>
<th>Quality Assessment</th>
<th>Summary of Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of Studies</td>
<td>Design</td>
</tr>
<tr>
<td>C: 0</td>
<td>Not reported</td>
</tr>
<tr>
<td>Major bleeding (follow-up 3-8 wk): Friedland et al, 2006</td>
<td></td>
</tr>
<tr>
<td>C: 1</td>
<td>Case series</td>
</tr>
<tr>
<td>0</td>
<td>Not reported</td>
</tr>
</tbody>
</table>


*Single-arm case series without comparison and no information on adjustment, blinding of outcome assessment, or patients lost to follow-up.
*Only 21 patients.
*Only one publication identified.
Table S2—[Section 2.4] PICO: In Patients Considered at High Risk for Perioperative Thromboembolism, Bridging Anticoagulation With Heparin/LMWH vs No Bridging

<table>
<thead>
<tr>
<th>No. of Studies</th>
<th>Design</th>
<th>Limitations</th>
<th>Indirectness</th>
<th>Inconsistency</th>
<th>Other Considerations</th>
<th>Effect</th>
<th>Relative (95% CI)</th>
<th>Absolute</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>I, C: 0</td>
<td>Observational study</td>
<td>Seriousa</td>
<td>Not relevant</td>
<td>No serious indirectness</td>
<td>Seriousb</td>
<td>No publication bias</td>
<td>Bridging Anticoagulation With a Heparin</td>
<td>5 events in 295 patients, pIR 0.02 [CI: 0.01-0.04]</td>
<td>Not reported</td>
<td>Not relevant</td>
</tr>
<tr>
<td>I, C: 0</td>
<td>Observational study</td>
<td>Seriousa</td>
<td>Not relevant</td>
<td>No serious indirectness</td>
<td>Seriousb</td>
<td>No publication bias</td>
<td>Major bleeding (follow-up 4 wk): Pengo et al, 2009</td>
<td>8 events in 295 patients, pIR 0.03 [CI: 0.01-0.05]</td>
<td>Not reported</td>
<td>Not relevant</td>
</tr>
<tr>
<td>I, C: 0</td>
<td>Observational study</td>
<td>Seriousa</td>
<td>Not relevant</td>
<td>No serious indirectness</td>
<td>Seriousb</td>
<td>No publication bias</td>
<td>Death (follow-up 4 wk): Pengo et al, 2009</td>
<td>1 event in 295 patients, pIR 0.0 [CI: 0.00-0.02]</td>
<td>Not relevant</td>
<td>Not relevant</td>
</tr>
</tbody>
</table>


a No information on adjustment, and blinding of outcome assessment.
b Sparse events.
### Table S3—[Section 2.4] PICO: In Patients Considered at Low Risk for Perioperative Thromboembolism, Bridging Anticoagulation With Heparin/LMWH vs No Bridging

<table>
<thead>
<tr>
<th>Quality Assessment</th>
<th>Summary of Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
</tr>
<tr>
<td></td>
<td>Bridging Anticoagulation With a Heparin</td>
</tr>
<tr>
<td>No. of Studies</td>
<td>Design</td>
</tr>
<tr>
<td>Thromboembolic event (follow-up 4 wk): Pengo et al, 2009</td>
<td>I: 1, C: 0</td>
</tr>
<tr>
<td>Major bleeding (follow-up 4 wk): Pengo et al, 2009</td>
<td>I: 1, C: 0</td>
</tr>
<tr>
<td>Death</td>
<td>0</td>
</tr>
</tbody>
</table>


*No specific information on adjustment, and blinding of outcome assessment.

*Sparse events.
<table>
<thead>
<tr>
<th>Quality Assessment</th>
<th>Summary of Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. of Studies</strong></td>
<td><strong>No. of Patients</strong></td>
</tr>
<tr>
<td><strong>Design</strong></td>
<td><strong>Limitations</strong></td>
</tr>
</tbody>
</table>

**Table S4**---*PICO: In Patients Receiving Warfarin Therapy and Having a Minor Dental Procedure, Continuing Warfarin and Coadministering an Oral Prohemostatic Drug vs Stopping Warfarin 5 to 6 Days Before Procedure Without Administering a Prohemostatic Drug (Observational Studies)*

### Thromboembolic event (follow-up 3mo)
- **C:** Russo et al, 2000; Saour et al, 1994

<table>
<thead>
<tr>
<th>No serious imprecision; judgment might change when frequencies are recalculated with the inverse variance method; however, no impact on overall judgment.</th>
</tr>
</thead>
</table>

### Major bleeding (follow-up 1-8d)

| No serious imprecision; judgment might change when frequencies are recalculated with the inverse variance method; however, no impact on overall judgment. |

### Moderate bleeding (follow-up 1-8d)

| No serious imprecision; judgment might change when frequencies are recalculated with the inverse variance method; however, no impact on overall judgment. |

### Minor bleeding (follow-up 1-8d)

| No serious imprecision; judgment might change when frequencies are recalculated with the inverse variance method; however, no impact on overall judgment. |

### Death: not reported

Bibliography:
Table S5—[Section 2.5] PICO: In Patients Receiving Warfarin Therapy and Having a Minor Dental Procedure, Continuing Warfarin and Coadministering an Oral Prohemostatic Drug vs Stopping Warfarin 5-6 Days Before Procedure Without Administering a Prohemostatic Drug (Randomized Trials)

<table>
<thead>
<tr>
<th>No. of</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>Quality Importance</td>
</tr>
<tr>
<td>No. of Studies</td>
<td>Design</td>
</tr>
<tr>
<td>Thromboembolic event: Borea et al, 1993; Evans et al, 2002; Sacco et al, 2006</td>
<td>3 RCT</td>
</tr>
<tr>
<td>Major bleeding (follow-up 1-8 d): Borea et al, 1993; Evans et al, 2002; Sacco et al, 2006</td>
<td>3 RCT</td>
</tr>
<tr>
<td>Moderate bleeding (follow-up 1-8 d): Borea et al, 1993; Evans et al, 2002; Sacco et al, 2006</td>
<td>3 RCT</td>
</tr>
<tr>
<td>Minor bleeding (follow-up 1-8 d): Borea et al, 1993; Evans et al, 2002</td>
<td>2 RCT</td>
</tr>
</tbody>
</table>

Death: not reported


\(^a\)No blinding of the patients, probably no blinding of the other research team members.

\(^b\)Few patients, few events, broad CIs include benefit as well as harm.
### Table S6—[Section 2.5] PICO: In Patients Receiving Warfarin Therapy and Having a Minor Skin Procedure, Continuing Warfarin Around the Time of the Procedure vs Stopping Warfarin 5-6 Days Before the Procedure

<table>
<thead>
<tr>
<th>No. of Patients</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. of Studies</strong></td>
<td><strong>Design</strong></td>
</tr>
<tr>
<td><strong>Continue VKA Around the Time of the Procedure</strong></td>
<td><strong>Stopping VKA Approximately 5 d Before the Procedure</strong></td>
</tr>
<tr>
<td><strong>Thromboembolic event: not reported</strong></td>
<td>Not reported</td>
</tr>
<tr>
<td><strong>Major bleeding (follow-up 24 h to 6 mo): I/C: Alcalay 2001; Billingsley and Maloney, 1997; Kargi et al, 2002; Syed 2004</strong></td>
<td></td>
</tr>
<tr>
<td>1: 4, C: 4</td>
<td>Prospective cohort</td>
</tr>
<tr>
<td><strong>Moderate bleeding (follow-up 24 h to 6 mo): I/C: Alcalay 2001; Billingsley and Maloney, 1997; Kargi et al, 2002; Syed et al, 2004</strong></td>
<td></td>
</tr>
<tr>
<td>1: 4, C: 4</td>
<td>Prospective cohort</td>
</tr>
<tr>
<td><strong>Minor bleeding (follow-up 24 h to 6 mo): I/C: Alcalay 2001; Billingsley and Maloney, 1997; Kargi et al, 2002; Syed et al, 2004</strong></td>
<td></td>
</tr>
<tr>
<td>1: 4, C: 4</td>
<td>Prospective cohort</td>
</tr>
<tr>
<td><strong>Death: not reported</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Bibliography:**

\(^a\)No information on adjustment, and blinding of outcome assessment.

\(^b\)Risk increase among studies varied between factor 0 and 10 (moderate bleeding event) and between factor 0 and 4.4 (minor bleeding event).

\(^c\)Small event rates in both groups.
Table S7—[Section 2.5] PICO: In Patients Receiving Warfarin Therapy and Having Cataract Removal, Continuing Warfarin Around the Time of the Procedure vs Stopping Warfarin 5 to 6 Days Before the Procedure

<table>
<thead>
<tr>
<th>Quality Assessment</th>
<th>Summary of Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>No. of patients</td>
</tr>
<tr>
<td>Continue VKA</td>
<td>Stopping VKAs</td>
</tr>
<tr>
<td>around the time</td>
<td>before the procedure</td>
</tr>
<tr>
<td>of the procedure</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. of studies</th>
<th>Design</th>
<th>Limitations</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other Considerations</th>
<th>No. of patients</th>
<th>Effect</th>
<th>Relative</th>
<th>Absolute</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>I: 2, C: 2</td>
<td>Prospective cohort, case series†</td>
<td>Serious§</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
<td>No publication bias</td>
<td>2 events in 1,165 patients§</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Low</td>
<td>Critical</td>
<td></td>
</tr>
<tr>
<td>Thromboembolic event: (follow-up 1 wk)</td>
<td>I: Hirschman 2006; Katz et al, 2003; C: Hirschman et al, 2006; Katz et al, 2003 (2 arms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I: 6, C: 6</td>
<td>Prospective cohort, case series†</td>
<td>Serious§</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
<td>No publication bias</td>
<td>0 events in 1,335 patients§</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Low</td>
<td>Critical</td>
<td></td>
</tr>
<tr>
<td>Major bleeding (follow-up median, 1 wk; range, 1/2 wk to 144 wk)</td>
<td>I: Fu 2007; Hirschman 2006; Katz et al, 2003; Narendran and Williamson, 2003; Rotenstreich et al, 2001; Wirbelauer et al, 2004; C: Hirschman 2006; Kallio et al, 2004 (2 arms); Katz et al, 2003 (2 arms); Lumme et al, 1994; Narendran and Williamson, 2003; Wirbelauer et al, 2004</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I: 6, C: 6</td>
<td>Prospective cohort, case series†</td>
<td>Serious§</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
<td>No publication bias</td>
<td>4 events in 1,335 patients§</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Low</td>
<td>Important</td>
<td></td>
</tr>
<tr>
<td>Moderate bleeding (follow-up median, 1 wk; range, 1/2 wk to 144 wk)</td>
<td>I: Fu 2007; Hirschman 2006; Katz et al, 2003; Narendran and Williamson, 2003; Rotenstreich et al, 2001; Wirbelauer et al, 2004; C: Hirschman 2006; Kallio et al, 2004 (2 arms); Katz et al, 2003 (2 arms); Lumme et al, 1994; Narendran and Williamson, 2003; Wirbelauer et al, 2004</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I: 6, C: 6</td>
<td>Prospective cohort, case series†</td>
<td>Serious§</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
<td>No publication bias</td>
<td>20 events in 1,335 patients§</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Low</td>
<td>Important</td>
<td></td>
</tr>
<tr>
<td>Minor bleeding (follow-up median, 1 wk; range, 1/2 wk to 144 wk)</td>
<td>I: Fu 2007; Hirschman 2006; Katz et al, 2003; Narendran and Williamson, 2003; Rotenstreich et al, 2001; Wirbelauer et al, 2004; C: Hirschman 2006; Kallio et al, 2004 (2 arms); Katz et al, 2003 (2 arms); Lumme et al, 1994; Narendran and Williamson, 2003; Wirbelauer et al, 2004</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death: not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


†In the presence of no events in many studies no pooling performed.
§Two of eight studies are cohort studies, six of eight studies are single-arm studies; no information on adjustment, and blinding of outcome assessment.
§Six of eight studies were cohort studies by design but four of six cohort studies contributed only one study arm to the profile (the alternative study arm did not match our PICO question). Those studies were treated like case series.
Table S8—[Section 3.5] PICO: Patient Receiving Antiplatelet Therapy and Having Elective Noncardiac Surgery, Continuing Antiplatelet Drugs Around the Time of the Procedure vs Stopping Antiplatelet Drugs 7 to 10 Days Before Noncardiac Surgery

<table>
<thead>
<tr>
<th>Quality Assessment</th>
<th>No. of Patients</th>
<th>Summary of Findings</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of Studies</td>
<td>Design Limitations</td>
<td>Inconsistency</td>
<td>Indirectness</td>
</tr>
<tr>
<td>1</td>
<td>RCTs No serious limitations No serious inconsistency No serious indirectness Serious None</td>
<td>235 of 6,679 (3.5%)</td>
<td>252 of 6,677 (3.8%)</td>
</tr>
<tr>
<td>1</td>
<td>RCTs No serious limitations No serious inconsistency Serious None</td>
<td>235 of 6,679 (3.5%)</td>
<td>252 of 6,677 (3.8%)</td>
</tr>
<tr>
<td>2</td>
<td>RCTs No serious limitations No serious inconsistency No serious indirectness Serious None</td>
<td>106 of 6,705 (1.6%)</td>
<td>80 of 6,704 (1.2%)</td>
</tr>
<tr>
<td>2</td>
<td>RCTs No serious limitations No serious inconsistency No serious indirectness Serious None</td>
<td>21 of 395 (5.3%)</td>
<td>44 of 374 (11.8%)</td>
</tr>
<tr>
<td>1</td>
<td>RCTs No serious limitations No serious inconsistency No serious indirectness Serious None</td>
<td>54 of 6,679 (0.8%)</td>
<td>49 of 6,677 (0.7%)</td>
</tr>
<tr>
<td>4</td>
<td>RCTs No serious limitations No serious inconsistency No serious indirectness Serious None</td>
<td>30 of 560 (5.4%)</td>
<td>37 of 538 (6.9%)</td>
</tr>
<tr>
<td>1</td>
<td>RCTs No serious limitations No serious inconsistency No serious indirectness Serious None</td>
<td>28 of 6,679 (0.4%)</td>
<td>38 of 6,677 (0.6%)</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>No. of Patients</th>
<th>Summary of Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Effect</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>No. of Patients</strong></td>
</tr>
</tbody>
</table>

### Quality Assessment Summary of Findings

<table>
<thead>
<tr>
<th>No. of Studies</th>
<th>Design</th>
<th>Limitations</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>RCTs</td>
<td>No serious limitations</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>Serious#</td>
<td>None</td>
</tr>
</tbody>
</table>

**Bleeding requiring transfusion (follow-up 1 mo): PEP-Trial 2000**

<table>
<thead>
<tr>
<th></th>
<th>Antiplatelet Drugs Continued</th>
<th>Stopping Antiplatelet Drugs</th>
<th>Relative (95% CI)</th>
<th>Absolute</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>197 of 6,679</td>
<td>157 of 6,677</td>
<td>RR, 1.24 (1.01-1.53)</td>
<td>6 more per 1,000</td>
<td>Moderate</td>
<td>Important</td>
<td></td>
</tr>
</tbody>
</table>

**Table S8—Continued**

Bibliography:
- MI = myocardial infarction; RR = relative risk; TIA = transient ischemic attack. See Table S1 and S5 legends for expansion of other abbreviations.

# CI includes four additional vascular deaths in 1,000 patients.
# McCollum et al: follow-up 3 y; Oscarsson: follow-up 1 mo.
# Event rate low (65 events in total).
# Rating down for imprecision: CI includes five additional strokes/TIA per 1,000 patients.
# CI includes 16 additional strokes/TIA in 1,000 patients.
# CI includes one additional PE in 1,000 patients.
# CI includes one additional bleeding event in 1,000 patients.
Supplementary Material
View e-supplements related to this article at:
http://chestjournal.chestpubs.org/content/suppl/2012/02/03/141.2_suppl.e326S.DC1.html

Updated Information & Services
Updated Information and services can be found at:
http://chestjournal.chestpubs.org/content/141/2_suppl/e326S.full.html

References
This article cites 214 articles, 73 of which can be accessed free at:
http://chestjournal.chestpubs.org/content/141/2_suppl/e326S.full.html#ref-list-1

Cited Bys
This article has been cited by 5 HighWire-hosted articles:
http://chestjournal.chestpubs.org/content/141/2_suppl/e326S.full.html#related-urls

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be
found online at:
http://www.chestpubs.org/site/misc/reprints.xhtml

Reprints
Information about ordering reprints can be found online:
http://www.chestpubs.org/site/misc/reprints.xhtml

Citation Alerts
Receive free e-mail alerts when new articles cite this article. To sign up, select the
“Services” link to the right of the online article.

Images in PowerPoint format
Figures that appear in CHEST articles can be downloaded for teaching purposes in
PowerPoint slide format. See any online figure for directions.